A Long Road To Recovery For Teva Pharmaceuticals; Morgan Stanley Downgrades

After a disastrous week last week for Teva Pharmaceutical Industries Ltd (ADR) TEVA 0.71% shareholders, this week is off to a bumpy start as well. Just days after Teva reported a second-quarter earnings miss, lowered guidance and slashed dividend by 75 percent, Morgan Stanley stepped in and downgraded the stock from Equal-Weight to Underweight.

Teva shares are down 36.3 percent in the past five trading sessions, but analyst David Risingersees more pain ahead. Morgan Stanley underestimated the impact that generic competition would have on Teva’s earnings potential, and the company has an uphill battle ahead fighting off generic competition to its top franchise, Copaxone.

“We believe that Teva’s disappointing generic business performance will take more time to improve given a combination of the generic industry’s intensifying secular challenges and Teva’s own difficulty in executing on its pipeline,” Risinger wrote on Monday.

Morgan Stanley expects Teva will continue to rely on debt to advance its pipeline, leaving the company in a precarious long-term position. The firm estimates Teva will operate with a debt/EBITDA ratio of around 4.0 through at least 2019.

Despite Teva losing more than a third of its market cap in a matter of days, Risinger said the stock’s 8.2 EV/EBITDA of 8.2 based on Morgan Stanley’s 2018 projections suggests the stock may still be overvalued at over $20 per share.

Looking ahead, the firm is forecasting…

Click here to continue reading

Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common SenseI don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!